- Home
- JFU vs GOVX Comparison
JFU vs GOVX Comparison
Compare JFU & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JFU
- GOVX
- Stock Information
- Founded
- JFU 2006
- GOVX 2001
- Country
- JFU China
- GOVX United States
- Employees
- JFU N/A
- GOVX N/A
- Industry
- JFU Finance: Consumer Services
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- JFU Finance
- GOVX Health Care
- Exchange
- JFU Nasdaq
- GOVX Nasdaq
- Market Cap
- JFU 17.8M
- GOVX 19.5M
- IPO Year
- JFU 2019
- GOVX N/A
- Fundamental
- Price
- JFU $1.58
- GOVX $1.77
- Analyst Decision
- JFU
- GOVX Strong Buy
- Analyst Count
- JFU 0
- GOVX 5
- Target Price
- JFU N/A
- GOVX $14.20
- AVG Volume (30 Days)
- JFU 5.0K
- GOVX 562.0K
- Earning Date
- JFU 01-01-0001
- GOVX 02-27-2025
- Dividend Yield
- JFU N/A
- GOVX N/A
- EPS Growth
- JFU N/A
- GOVX N/A
- EPS
- JFU 0.09
- GOVX N/A
- Revenue
- JFU $40,614,155.00
- GOVX $3,090,161.00
- Revenue This Year
- JFU N/A
- GOVX N/A
- Revenue Next Year
- JFU N/A
- GOVX $150.51
- P/E Ratio
- JFU $16.63
- GOVX N/A
- Revenue Growth
- JFU N/A
- GOVX N/A
- 52 Week Low
- JFU $1.13
- GOVX $1.09
- 52 Week High
- JFU $3.75
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- JFU 54.21
- GOVX 31.12
- Support Level
- JFU $1.47
- GOVX $1.85
- Resistance Level
- JFU $1.59
- GOVX $2.24
- Average True Range (ATR)
- JFU 0.04
- GOVX 0.16
- MACD
- JFU 0.01
- GOVX -0.03
- Stochastic Oscillator
- JFU 80.00
- GOVX 11.38
About JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company generates the majority of its revenue from Loan facilitation services. All its revenues are generated from the People's Republic of China.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.